Maria Rosaria Pricolo

Dr. Maria Rosaria Pricolo


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
MAMahmoud Abdellatif
Mahmoud Abdellatif
VTViktoria Trummer-Herbst
Viktoria Trummer-Herbst
FKFranziska Koser
Franziska Koser
SDSylvère Durand
Sylvère Durand
RARui Adão
Rui Adão
SSSedej Simon
Sedej Simon
The NAD + precursor nicotinamide improves diastolic dysfunction caused by aging, hypertension, or metabolic syndrome in rodents.

1 February 2012 in Cancer Letters
Verified
Journal Article
Closed access
BIBarbara Iovine
Barbara Iovine
MIMaria Luigia Iannella
Maria Luigia Iannella
FNFrancesca Nocella
Francesca Nocella
MPMaria Rosaria Pricolo
Maria Rosaria Pricolo
MBMaria Assunta Bevilacqua
Maria Assunta Bevilacqua

1 July 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CSCarmen Suay-Corredera
Carmen Suay-Corredera
MPMaria Rosaria Pricolo
Maria Rosaria Pricolo
EHElías Herrero-Galán
Elías Herrero-Galán
DVDiana Velázquez-Carreras
Diana Velázquez-Carreras
DSDavid Sánchez-Ortiz
David Sánchez-Ortiz
JAJorge Alegre-Cebollada
Jorge Alegre-Cebollada
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Variants in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are the leading cause of HCM. However, the pathogenicity status of hundreds of MYBPC3 variants found in patients remains unknown, as a consequence of our incomplete understanding of the pathomechanisms triggered by HCM-causing variants. Here, we examined 44 nontruncating MYBPC3 variants that we classified as HCM-linked or nonpathogenic according to cosegregation and population genetics criteria. We found that around half of the HCM-linked variants showed alterations in RNA splicing or protein stability, both of which can lead to cMyBP-C haploinsufficiency. These protein haploinsufficiency drivers associated with HCM pathogenicity with 100% and 94% specificity, respectively. Furthermore, we uncovered that 11% of nontruncating MYBPC3 variants currently classified as of uncertain significance in ClinVar induced one of these molecular phenotypes. Our strategy, which can be applied to other conditions induced by protein loss of function, supports the idea that cMyBP-C haploinsufficiency is a fundamental pathomechanism in HCM.

Verified
Journal Article
Open access
PDF file
Giulia FrissoGiulia Frisso
Giulia Frisso
NDNicola Detta
Nicola Detta
PCPamela Coppola
Pamela Coppola
Cristina MazzaccaraCristina Mazzaccara
Cristina Mazzaccara
MPMaria Rosaria Pricolo
Maria Rosaria Pricolo
FSFrancesco Salvatore
Francesco Salvatore
Point mutations are the most common cause of inherited diseases. Bioinformatics tools can help to predict the pathogenicity of mutations found during genetic screening, but they may work less well in determining the effect of point mutations in non-coding regions. In silico analysis of intronic variants can reveal their impact on the splicing process, but the consequence of a given substitution is generally not predictable. The aim of this study was to functionally test five intronic variants (MYBPC3-c.506-2A>C, MYBPC3-c.906-7G>T, MYBPC3-c.2308+3G>C, SCN5A-c.393-5C>A, and ACTC1-c.617-7T>C) found in five patients affected by inherited cardiomyopathies in the attempt to verify their pathogenic role. Analysis of the MYBPC3-c.506-2A>C mutation in mRNA from the peripheral blood of one of the patients affected by hypertrophic cardiac myopathy revealed the loss of the canonical splice site and the use of an alternative splicing site, which caused the loss of the first seven nucleotides of exon 5 (MYBPC3-G169AfsX14). In the other four patients, we generated minigene constructs and transfected them in HEK-293 cells. This minigene approach showed that MYBPC3-c.2308+3G>C and SCN5A-c.393-5C>A altered pre-mRNA processing, thus resulting in the skipping of one exon. No alterations were found in either MYBPC3-c.906-7G>T or ACTC1-c.617-7T>C. In conclusion, functional in vitro analysis of the effects of potential splicing mutations can confirm or otherwise the putative pathogenicity of non-coding mutations, and thus help to guide the patient's clinical management and improve genetic counseling in affected families.

30 May 2023 in Circulation
Verified
Journal Article
Closed access
FDFernando Domínguez
Fernando Domínguez
LLLaura Lalaguna
Laura Lalaguna
IMInés Martínez-Martín
Inés Martínez-Martín
JFJesús Piqueras Flores
Jesús Piqueras Flores
TRTorsten Bloch Rasmussen
Torsten Bloch Rasmussen
PGPablo García-Pavía
Pablo García-Pavía

7 February 2020 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
MPMaria Rosaria Pricolo
Maria Rosaria Pricolo
EHElías Herrero-Galán
Elías Herrero-Galán
Cristina MazzaccaraCristina Mazzaccara
Cristina Mazzaccara
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
JAJorge Alegre-Cebollada
Jorge Alegre-Cebollada
Giulia FrissoGiulia Frisso
Giulia Frisso